Genetic factors associated with skin cancer in renal transplant patients

Photodermatology Photoimmunology and Photomedicine

Volumn 23, Issue 2-3, 2007, Pages 62-67

  Laing, Mary Elizabeth ^a   Kay, Elaine ^a   Conlon, Peter ^a   Murphy, Gillian M ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Genetic polymorphisms; Renal transplant patients; Skin cancer

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; GLUTATHIONE TRANSFERASE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; MELANOCORTIN 1 RECEPTOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; VITAMIN D RECEPTOR;

CANCER DIAGNOSIS; CANCER RISK; DNA DAMAGE; DNA METHYLATION; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; IMMUNE DEFICIENCY; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN CANCER; SKIN CARCINOGENESIS; SKIN COLOR; SKIN PROTECTION; ULTRAVIOLET RADIATION;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY TRANSPLANTATION; POLYMORPHISM, GENETIC; RISK FACTORS; SKIN NEOPLASMS;

EID: 34249795151     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2007.00282.x     Document Type: Review

References (58)

1. Gibson GE. Evaluation of risk factors for cutaneous malignancy in renal transplant recipients. MD thesis, UCC, NUI, 1995.
2. Moloney FJ, Comber H, O'Lorcain P, et al. A population-based study of skin cancer incidence and prevalence in renal transplant recipients. Br J Dermatol 2006; 154: 498-504.
3. Choi SW, Mason JB. Folate and carcinogenesis: An integrated scheme. J Nutr 2000; 130: 129-132.
4. Frosst P, Blom HJ, Milos R, et al. Candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
5. Laing ME, Dicker P, Conlon P, et al. Association of methylenetetrahydrofolate reductase (MTHFR) polymorphism and the risk of squamous cell carcinoma in renal transplant patients. Bri J Dermatol 2006 (abstract); ISS s1: 10-13.
6. Chiles MC, Ai L, Zuo C, et al. E-cadherin promoter hypermethylation in preneoplastic and neoplastic skin lesions. Mod Pathol 2003; 16: 1014-1018.
7. Fraga MF, Herranz M, Espada J, et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumours. Cancer Res 2004; 64: 5527-5534.
8. Shannon RL, Strayer DS. Arsenic-induced skin toxicity. Hum Toxicol 1989; 8: 99-104.
9. Huang C, Ke Q, Costa M, et al. Molecular mechanisms of arsenic carcinogenesis. Mol Cell Biochem 2004; 255: 57-66.
10. Sciandrello G, Caradonna F, Mauro M, et al. Arsenic induced DNA hypomethylation affects chromosomal instability in mammalian cells. Carcinogenesis 2004; 25: 413-417.
11. Sutherland JE, Costa M. Epigenetics and the environment. Ann NY Acad Sci 2003; 983: 151-160.
12. Pacifica A. Ananthaswamy HN, personal communication
13. de Gruijl FR. Photocarcinogenesis: UVA vs UVB radiation. Skin Pharmacol Appl Skin Physiol 2002; 15: 316-320.
14. Matsumara Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol 2004; 195: 298-308.
15. Sharonov A, Gustavsson T, Marguet S, et al. Photophysical properties of 5-methylcytidine. Photochem Photobiol Sci 2003; 2: 362-364.
16. Tommasi S, Denissenko MF, Pfeifer GP. Sunlight induces pyrimidine dimers preferentially at 5 methylcytosine bases. Cancer Res 1997; 57: 4727-4730.
17. Pfeifer GP p53 metational spectra and the role of methylated CpG sequences. Mutat Res 2000; 450: 155-166.
18. Denissenko MF, Chen JX, Tang MS, et al. Cytosine methylation determines hot spots of DNA damage in the human p53 gene. Proc Natl Acad Sci USA 1997; 94: 3893-3898.
19. You YH, Pfeifer GP. Similarities in sunlight-induced mutational spectra of GpG-methylated transgenes and the p53 gene in skin cancer point to an important role of 5-methylcytosine residues in solar UV mutagenesis. J Mol Biol 2001; 305: 389-399.
20. Mittal A, Piyathilake C, Hara Y, et al. Exceptionally high protection of photocarcinogenesis by topical application of epigallocatechin-3-gallate in hydrophilic cream in SKH-1 hairless mouse model: Relationship to inhibition of UVB-induced global DNA hypomethylation. Neoplasia 2003; 5: 555-565.
21. Giglia- Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat 2003; 21: 217-228.
22. Peterson EJ, Bogler O, Taylor SM. p53-mediated repression of DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 2003; 14: 766-774.
23. Van Doorn R, Gruis NA, Willemze R, et al. Aberrant DNA methylation in cutaneous malignancies. Semin Oncol 2005; 32: 479-487.
24. Off MK, Steindal AE, Porojnicu AC, Juzeniene A, Vorobey A, Johnsson A, Moan J. Ultraviolet photodegradation of folic acid. J Photochem Photobiol B: Biol 2005; 80: 47-55.
25. Branda RF, Eaton JW. Skin color and nutrient photolysis: An evolutionary Hypothesis. Science 1978; 201: 625-626.
26. Cohn BA. Sunlight, skin color, and folic acid. J Am Acad Dermatol 2002; 46: 317-318.
27. Jablonski NG. Sun, skin colour and spina bifida: An exploration of the relationship between ultraviolet light and neural tube defects. Proc Australas Soc Hum Biol 1992; 5: 455-462.
28. Jablonski NG. A possible link between neural tuble defects and ultraviolet light exposure. Med Hypotheses 1999; 52: 581-582.
29. Lapunzina P. Ultraviolet light-related neural tube defects? Am J Med Genet 1996; 67: 106.
30. Jablonski NG. UV light induced neural tube defects in amphibian larvae and their implications for the evolution of melanized pigmentation and declines in amphibian populations. J Herpetol 1998; 32: 455-457.
31. Healy E. Melanocortin 1 receptor variants, pigmentation and skin cancer susceptibility. Photodermatol Photoimmunol Photomed 2004; 20: 283.
32. Bastiaens MT, ter Huurne JA, Kielich C, et al. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet 2001; 68: 884-894.
33. Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11: 328-330.
34. Box NF, Duffy DL, Irving RE, et al. Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J Invest Dermatol 2001; 116: 224-229.
35. Valverde P, Healy E, Sikkink S, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996; 5: 1663-1666.
36. Kennedy C, ter Huurne J, Berkhout M, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001; 117: 294-300.
37. Moloney FJ. Epidermological, genetic and cellular studies of skin cancer in renal transplant recipients. MD thesis. NUI, Galway. October 2005.
38. Marshall SE, Bordea C, Haldar NA, et al. Glutathione S -transferase polymorphisms and skin cancer after renal transplantation. Kidney Int 2000; 58: 2186-2193.
39. Heagerty A, Smith A, English J, et al. Suscepitbility to multiple cutaneous basal cell carcinomas: Significant interactions between gluththione S transferase GSTM1 genotypes, skin type and male gander. Br J Cancer 1996; 73: 44-48.
40. Heagerty AH, Fitzgerald D, Smith A, et al. Glutathione S- transferase GSTM1 phenotypes and protection against cutaneous tumours. Lancet 1994; 343: 266-268.
41. Lear JT, Heagerty AH, Smith A, et al. Multiple cutaneous basal cell carcinomas: Glutathione S -transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. Carcinogenesis 1996; 17: 1891-1896.
42. Ramsay HM, Harden PN, Reece S, et al. Polymorphisms in glutathione S -transferase are associated with altered risk on nonmelanoma skin cancer in renal transplant recipients: A preliminary analysis. J Invest Dermatol 2001; 117: 251-255.
43. Fraser PA, Ding WZ, Mohseni M, et al. Glutathione S -transferase M null homozygosity and risk of systemic lupus erythematosus associated with sun exposure: A possible gene-environment interaction for autoimmunity. J Rheumatol 2003; 30: 276-282.
44. May P, May E. Twenty years of p53 research: Structural and functional aspects of the p53 protein. Oncogene 1999; 18: 7621-7636.
45. Matlashewski GJ, Tuck S, Pim D, et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987; 7: 961-963.
46. Thomas M, Kalita A, Labrecque S, et al. Two polymorphic forms of wild type3 p53 differ biochemically and biologically. Mol Cell Biol 1999; 2: 1092-1100.
47. Storey A, Thomas M, Kalita A, et al. Role of p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-234.
48. Cairey-Remonnay S, Humbey O, Mougin C, et al. TP53 polymorphism of exon 4 at codon 72 in cutaneous squamous cell carcinoma and benign epithelial lesions of renal transplant recipients and immunocompetent individuals: lack of correlation with human papillomavirus status. J Invest Dermatol 2002; 118: 1026-1031.
49. O'Connor DP, Kay EW, Leader M, et al. p53 codon 72 polymorphism and human papillomavirus associated skin cancer. J Clin Pathol 2001; 54: 539-542.
50. Quinn AG, Campbell C, Healy E, et al. Chromosome 9 allele loss occurs in both basal and squamous cell carcinomas of the skin. J Invest Dermatol 1994; 102: 300-303.
51. Ahmadian A, Ren ZP, Williams C, et al. Genetic instability in the 9q22.3 region is a late event in the development of squamous cell carcinoma. Oncogene 1998; 17: 1837-1843.
52. O'Connor DP, Kay EW, Leader M, et al. A high degree of chromosomal instability at 13q14 in cutaneous squamous cell carcinomas: Indication for a role of a tumour suppressor gene other than RB. Mol Pathol 2001; 54: 165-169.
53. Almartine EJ, Berthoux P, Mariat C, et al. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol 2003; 120: 99-103.
54. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8.
55. Hutchinson PE, Osborne JE, Lear JT, et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000; 6: 498-504.
56. Laing ME, Dicker P, Moloney FJ, et al. Vitamin D receptor polymorphisms have no association with NMSC in renal transplant patients. J Am Acad Dermatol 2007; 56 (2) s AB 146 (abstract).
57. Lavin P, Laing ME, O'Kelly P, Moloney FJ, Murphy GM, Conlon P. FokI Polymorphism is associated with improved renal allograft survival. World Transplant Congress, Boston, July 2006 (abstract).
58. Gambaro G, Anglani F, D'Angelo Association studies of genetic polymorphisms and complex disease. Lancet 2000; 355: 308-311.